muscle loss glp 1 Weight with GLP-1 medicines does not result in a disproportionate loss of mass or function in obese mice and humans Muscle loss and GLP-1R agonists

As fat mass decreases, inflammation levels often improve, and the bodys metabolic demands shift

Clinical trials using imaging techniques such as MRI and CT scans have shown that GLP-1 receptor agonists lead to reductions in both subcutaneous fat (beneath the skin) and visceral fat

Patients on GLP-1 drugs tend to have EWDR for one to two years after rapid A1c improvement

However, both substances can influence glucose levels, blood pressure, and gastrointestinal function, warranting provider oversight

It can be very confusing to sort out whats applicable to you, he says

Discuss permanent schedule changes with your provider to ensure proper documentation